Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,707 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,707 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Enrollment posture brief
Registry condition hiv-infections
OPEN 56 | RECR 9% | LATE 92 | EARLY 266 | RANK #7 | SPON 195
Volume-matched condition peers
Nearest open-share peer: Acute Lung Injury (9% recruiting · 11 trials)
HIV Infections lists 56 open slots (9% of 615 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 9 of 13
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006152
Impact of Antiretroviral Therapy on Cardiac Biomarkers
University of California, Davis
NCT00641888
Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers
Rockefeller University
NCT00545987
The Safety and Effectiveness of Megace in HIV-Infected Women
Bristol-Myers Squibb
NCT00002345
A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
National Cancer Institute (NCI)
NCT00001681
Disulfiram Interactions With HIV Medications: Clinical Implications
University of California, San Francisco
NCT00878306
mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention
Columbia University
NCT06059443
Phase I Trial of S-1153 in Patients With HIV Infection
Lexigen Pharmaceuticals
NCT00002214
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000984
Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00053430
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
Albert Einstein College of Medicine
NCT01108679
Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02411539
PTSD and Risk Behavior in HIV Positive Female Adolescents
University of North Carolina, Chapel Hill
NCT00271882
A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
ViiV Healthcare
NCT04263142
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
Otsuka America Pharmaceutical
NCT00002129
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000738
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
Boehringer Ingelheim
NCT00002194
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000987
Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00083330
Effects of TENS and Mindfulness Meditation in Persons With HIV-related Neuropathy
Rutgers University
NCT04868123
Dexamethasone in Cryptococcal Meningitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000776
Phase 1 Safety Study of Two Experimental HIV Vaccines
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00479999
Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use
University of California, Los Angeles
NCT02603471
Pain Inflammation and Cannabis in HIV
Montefiore Medical Center
NCT05554146
Treatment De-Intensification and Residual HIV-1 in Youth
University of North Carolina, Chapel Hill
NCT00867854
Mesalamine to Reduce T Cell Activation in HIV Infection
University of California, San Francisco
NCT01090102
Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center
Centers for Disease Control and Prevention
NCT00267410
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04212091
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000801
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001027
A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000798
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00102089
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000877
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
University of California, San Francisco
NCT00879047
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Duke University
NCT00887679
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
Novartis
NCT00002394
A Study of Lobucavir in Patients With AIDS
Bristol-Myers Squibb
NCT00002352
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000845
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00046267
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000753
CCR5-modified CD4+ T Cells for HIV Infection
University of Cincinnati
NCT03666871
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Hoffmann-La Roche
NCT00002143
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
Gilead Sciences
NCT00036634
A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001004
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
ViiV Healthcare
NCT01568892
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
Merck Sharp & Dohme
NCT00002361
A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03856996
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
University of Pennsylvania
NCT00428519
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00012519
Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects
Duquesne University
NCT00696839
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infections page
615 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 HIV Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infections condition card totals 615 registered trials; most-linked intervention Zidovudine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.